CAR-T细胞治疗实体瘤的现状研究

doi:10.3969/j.issn.1000-8535.2023.09.001

摘要/Abstract

摘要： 肿瘤免疫治疗是指利用人体的免疫机制,通过主动或被动的方法增强患者免疫功能,达到杀伤肿瘤细胞的目的。嵌合抗原受体T细胞（CAR-T）作为肿瘤免疫治疗的新型精准靶向疗法,近几年通过优化和改良已成功应用于多种血液肿瘤的治疗,是目前恶性肿瘤治疗中最有潜力的疗法之一。但由于实体瘤中存在显著的异质性和复杂的肿瘤免疫微环境,CAR-T在实体瘤中的应用仍面临诸多挑战。本文将对目前 CAR-T 细胞治疗实体瘤的研究成果、现存挑战及相应的优化策略进行综述,以期为后续 CAR-T 细胞治疗实体肿瘤研究提供参考。

关键词: 嵌合抗原受体T细胞（CAR-T）, 肿瘤免疫治疗, 实体瘤

Abstract: Tumor immunotherapy is the process of enhancing patients’ immune system through active or passive methods to achieve the goal of eliminating tumor cells．Through optimization and modification,chimeric antigen receptor T cells（CAR-T）,a novel precise targeted therapy of cancer immunotherapy,have been successfully used in the treatment of several hematological malignancies in recent years．CAR-T is considered as one of the most promising therapies for the treatment of malignant tumors at the moment．However,application of CAR-T in solid tumors still confronts several difficulties due to the high heterogeneity and intricate tumor immune microenvironment．To serve as a reference for future CAR-T cell therapy for solid tumors,the present research findings,current difficulties and associated optimization techniques are reviewed in this paper．

Key words: CAR-T, immunotherapy, solid tumors

彭倩, 吕琳. CAR-T细胞治疗实体瘤的现状研究[J]. 广州医药, 2023, 54(9): 1-10.

PENG Qian, LV Lin. Recent advances in solid tumor CAR-T cell therapy[J]. Guangzhou Medical Journal, 2023, 54(9): 1-10.

参考文献

[1] HE W,LI Q,LU Y,et al.Cancer treatment evolution from traditional methods to stem cells and gene therapy[J].Curr Gene Ther,2022,22(5):368-385.
[2] AHMAD A.CAR-T Cell Therapy[J].Int J Mol Sci,2020,21(12):4303.
[3] AHMAD A,UDDIN S,STEINHOFF M.CAR-T cell therapies:An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-Cell lymphomas[J].Int J Mol Sci,2020,21(11):3906.
[4] ZHANG W Y,WANG Y,GUO Y L,et al.Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma:an early phase IIa trial report[J].Sig Transduct Target Ther,2016,1:16002.
[5] TILL B G,JENSEN M C,WANG J,et al.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells[J].Blood,2008,112(6):2261-2271.
[6] SADELAIN M,RIVIERE I,BRENTJENS R.Targeting tumours with genetically enhanced T lymphocytes[J].Nat Rev Cancer,2003,3(1):35-45.
[7] RAMOS C A,DOTTI G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
[8] HUANG S,WANG X,WANG Y,et al.Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies[J].Mol Cancer,2023,22(1):80.
[9] HARDING F A,MCARTHUR J G,GROSS J A,et al.CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones[J].Nature,1992,356(6370):607-609.
[10] LENSCHOW D J,WALUNAS T L,BLUESTONE J A.CD28/B7 system of T cell costimulation[J].Annu Rev Immunol,1996(14):233-258.
[11] TILL B G,JENSEN M C,WANG J,et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains:pilot clinical trial results[J].Blood,2012,119(17):3940-3950.
[12] MORGAN R A,YANG J C,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843-851.
[13] CHMIELEWSKI M,ABKEN H.TRUCKs:the fourth generation of CARs[J].Expert Opin Biol Ther,2015,15(8):1145-1154.
[14] KAGOYA Y,TANAKA S,GUO T,et al.A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects[J].Nat Med,2018,24(3):352-359.
[15] NASIRI F,KAZEMI M,MIRAREFIN S,et al.CAR-T cell therapy in triple-negative breast cancer:Hunting the invisible devil[J].Front Immunol,2022(13):1018786.
[16] O’ROURKE D M,NASRALLAH M P,DESAI A,et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J].Sci Transl Med,2017,9(399):eaaa0984.
[17] ZHANG Y,ZHANG Z,DING Y,et al.Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients[J].J Cancer Res Clin Oncol,2021,147(12):3725-3734.
[18] GUO Y,FENG K,LIU Y,et al.Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J].Clin Cancer Res,2018,24(6):1277-1286.
[19] BROWN C E,WARDEN C D,STARR R,et al.Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis[J].PLoS One,2013,8(10):e77769.
[20] BROWN C E,BADIE B,BARISH M E,et al.Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma[J].Clin Cancer Res,2015,21(18):4062-4072.
[21] BROWN C E,RODRIGUEZ A,PALMER J,et al.Off-the-shelf,steroid-resistant,IL13Rα2-specific CAR T cells for treatment of glioblastoma[J].Neuro Oncol,2022,24(8):1318-1330.
[22] ORDONEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol,2003,27(11):1418-1428.
[23] PANG N,SHI J,QIN L,et al.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin[J].J Hematol Oncol,2021,14(1):118.
[24] KLAMPATSA A,DIMOU V,ALBELDA S M.Mesothelin-targeted CAR-T cell therapy for solid tumors[J].Expert Opin Biol Ther,2021,21(4):473-486.
[25] ADUSUMILLI P S,ZAUDERER M G,RIVIERE I,et al.A Phase I Trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the Anti-PD-1 agent pembrolizumab[J].Cancer Discov,2021,11(11):2748-2763.
[26] WAGNER S,MULLINS C S,LINNEBACHER M.Colorectal cancer vaccines:Tumor-associated antigens vs neoantigens[J].World J Gastroenterol,2018,24(48):5418-5432.
[27] CHABANNON C,BONINI C.Structure of and Signalling Through Chimeric Antigen Receptor[M].Cham(CH):Springer,2022:3-5.
[28] RAMAKRISHNA S,HIGHFILL S L,WALSH Z,et al.Modulation of target antigen density improves CAR T-cell functionality and persistence[J].Clin Cancer Res,2019,25(17):5329-5341.
[29] GARDNER R A,FINNEY O,ANNESLEY C,et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults[J].Blood,2017,129(25):3322-3331.
[30] ANURATHAPAN U,CHAN R C,HINDI H F,et al.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells[J].Mol Ther,2014,22(3):623-633.
[31] FRY T J,SHAH N N,ORENTAS R J,et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy[J].Nat Med,2018,24(1):20-28.
[32] GENDUSO S,FREYTAG V,SCHETLER D,et al.Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo[J].J Hematol Oncol,2023,16(1):23.
[33] ARNOLD S,KORTLAND J,MALTSEVA D V,et al.Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules,promotes pulmonary metastasis,and reduces survival in a spontaneous xenograft model of human breast cancer[J].J Cancer Res Clin Oncol,2022,148(6):1525-1542.
[34] ZHOU F,ZHANG F,ZARNITSYNA V I,et al.The kinetics of E-selectin-and P-selectin-induced intermediate activation of integrin αLβ2 on neutrophils[J].J Cell Sci,2021,134(18):jcs258046.
[35] LEE J,SONG K H,KIM T,et al.Endothelial cell focal adhesion regulates transendothelial migration and subendothelial crawling of T cells[J].Front Immunol,2018(9):48.
[36] MARTINEZ M,MOON E K.CAR T Cells for Solid Tumors:New Strategies for finding,infiltrating,and surviving in the tumor microenvironment[J].Front Immunol,2019(10):128.
[37] VEDVYAS Y,MCCLOSKEY J E,YANG Y,et al.Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy[J].Sci Rep,2019,9(1):10634.
[38] GEORGANAKI M,RAMACHANDRAN M,TUIT S,et al.Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy[J].Oncoimmunology,2020,9(1):1730538.
[39] BUCKANOVICH R J,FACCIABENE A,KIM S,et al.Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy[J].Nat Med,2008,14(1):28-36.
[40] HENKE E,NANDIGAMA R,ERGUN S.Extracellular matrix in the tumor microenvironment and its impact on cancer therapy[J].Front Mol Biosci,2020(6):160.
[41] NISSEN N I,KARSDAL M,WILLUMSEN N.Collagens and cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology[J].J Exp Clin Cancer Res,2019,38(1):115.
[42] PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
[43] PARK J,HSUEH P C,LI Z,et al.Microenvironment-driven metabolic adaptations guiding CD8(+)T cell anti-tumor immunity[J].Immunity,2023,56(1):32-42.
[44] JIANG W,HE Y,HE W,et al.Exhausted CD8+T Cells in the tumor immune microenvironment:New pathways to therapy[J].Front Immunol,2020(11):622509.
[45] PIETROBON V,TODD L A,GOSWAMI A,et al.Improving CAR T-Cell Persistence[J].Int J Mol Sci,2021,22(19):10828.
[46] WERB Z,LU P.The role of stroma in tumor development[J].Cancer J,2015,21(4):250-253.
[47] CHEN Y,MCANDREWS K M,KALLURI R.Clinical and therapeutic relevance of cancer-associated fibroblasts[J].Nat Rev Clin Oncol,2021,18(12):792-804.
[48] OYA Y,HAYAKAWA Y,KOIKE K.Tumor microenvironment in gastric cancers[J].Cancer Sci,2020,111(8):2696-2707.
[49] HU D,LI Z,ZHENG B,et al.Cancer-associated fibroblasts in breast cancer:Challenges and opportunities[J].Cancer Commun(Lond),2022,42(5):401-434.
[50] WANG X,WANG L,MO Q,et al.Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients[J].Int J Clin Exp Pathol,2015,8(5):5702-5708.
[51] SHAN T,CHEN S,CHEN X,et al.M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway[J].Oncol Rep,2020,44(5):1885-1894.
[52] WU L,ZHANG X H.Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic[J].Front Immunol,2020(11):553967.
[53] HEGDE M,MUKHERJEE M,GRADA Z,et al.Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape[J].J Clin Invest,2016,126(8):3036-3052.
[54] LIANG Z,DONG J,YANG N,et al.Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer[J].Int J Biol Sci,2021,17(15):4365-4376.
[55] ZHANG M,CHEN D,FU X,et al.Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J].Clin Cancer Res,2022,28(13):2830-2843.
[56] KATSAROU A,SJOSTRAND M,NAIK J,et al.Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence[J].Sci Transl Med,2021,13(623):eabh1962.
[57] HEGDE M,CORDER A,CHOW K K,et al.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma[J].Mol Ther,2013,21(11):2087-2101.
[58] KAKARLA S,CHOW K K,MATA M,et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma[J].Mol Ther,2013,21(8):1611-1620.
[59] JIN L,TAO H,KARACHI A,et al.CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors[J].Nat Commun,2019,10(1):4016.
[60] van SCHALKWYK M C,PAPA S E,JEANNON J P,et al.Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer[J].Hum Gene Ther Clin Dev,2013,24(3):134-142.
[61] PAPA S,van SCHALKWYK M,MAHER J.Clinical evaluation of ErbB-targeted CAR T-Cells,following intracavity delivery in patients with ErbB-expressing solid tumors[J].Methods Mol Biol,2015(1317):365-382.
[62] ZHANG B L,QIN D Y,MO Z M,et al.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors[J].Sci China Life Sci,2016,59(4):340-348.
[63] BERNFIELD M,GOTTE M,PARK P W,et al.Functions of cell surface heparan sulfate proteoglycans[J].Annu Rev Biochem,1999(68):729-777.
[64] CARUANA I,SAVOLDO B,HOYOS V,et al.Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes[J].Nat Med,2015,21(5):524-529.
[65] SONG W,ZHANG M.Use of CAR-T cell therapy,PD-1 blockade,and their combination for the treatment of hematological malignancies[J].Clin Immunol,2020(214):108382.
[66] MCGOWAN E,LIN Q,MA G,et al.PD-1 disrupted CAR-T cells in the treatment of solid tumors:Promises and challenges[J].Biomed Pharmacother,2020(121):109625.
[67] WANG H,KAUR G,SANKIN A I,et al.Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies[J].J Hematol Oncol,2019,12(1):59.
[68] LONG A H,HIGHFILL S L,CUI Y,et al.Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas[J].Cancer Immunol Res,2016,4(10):869-880.
[69] GARCIA-GUERRERO E,RODRIGUEZ-LOBATO L G,SIERRO-MARTINEZ B,et al.All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells[J].Haematologica,2023,108(2):568-580.
[70] AGLIARDI G,LIUZZI A R,HOTBLACK A,et al.Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma[J].Nat Commun,2021,12(1):444.
[71] TANG N,CHENG C,ZHANG X,et al.TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors[J].JCI Insight,2020,5(4):133977.
[72] Correction:Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer[J].J Immunother Cancer,2020,8(1):e000676corr1.